Emerging Role of Circulating Tumor Cells in Gastric Cancer
Authors:
- Phung Thanh HuongPHPhung Thanh Huong
- Sanjeev GurshaneySGSanjeev Gurshaney
- Nguyen Thanh BinhNBNguyen Thanh Binh
- Anh Gia PhamAnh Gia Pham
- Huy Hoang NguyenHNHuy Hoang Nguyen
- Xuan Thanh NguyenXNXuan Thanh Nguyen
- Hai Pham-TheHai Pham-The
- Phuong-Thao TranPTPhuong-Thao Tran
- Khanh Truong VuKVKhanh Truong Vu
- Nhuong Xuan DuongNDNhuong Xuan Duong
- Claudio PelucchiCPClaudio Pelucchi
- Carlo La VecchiaCarlo La Vecchia
Open Access
Abstract
With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.Keywords
Funding Information
- Start-up Fund-University of Pittsburgh Medical Center (NA)
This publication has 116 references indexed in Scilit:
- Three Functions of Cadherins in Cell AdhesionCurrent Biology, 2013
- Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysisBMC Cancer, 2013
- Detecting Circulating Tumor Cells: Current Challenges and New TrendsTheranostics, 2013
- Circulating Tumor Cells as a Window on Metastasis Biology in Lung CancerThe American Journal of Pathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor ProgressionJournal of Mammary Gland Biology and Neoplasia, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Cancer survival discrepancies in developed and developing countries: comparisons between the Philippines and the United StatesBritish Journal of Cancer, 2009
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- Metastasis genes: A progression puzzleNature, 2002